Search PubMed⌕ Search

Biomedical subjects

Y Takeda

Publications and source records attributed to Y Takeda.

At least 757 records · Page 42Linked to original sources
PubMed1992

[Urodynamic study on urinary disturbance after therapy of uterine cancer].

It is well known that urinary disturbance often appears after radical hysterectomy for uterine cancer and is aggravated by additional radiation therapy. The aim of this study is to elucidate the pathogenesis and to establish the treatment method of urinary disturbance after therapy for uterine cancer. Forty-five patients with urinary disturbance and ten normal controls were subjected to this study. Changes in clinical symptoms and findings in the Urodynamic study (UDS) in 12 severe cases were investigated before and after treatment with beta 2-stimulant (Mabuterol HCL). Clinical symptoms in cases treated by radiation therapy alone were rare and mild without any pad exchanges, and appeared 5 years after treatment for uterine cancer. Findings of UDS in these cases were mild low compliance of detrusor at maximum desire to void (Cmdv) and mild low bladder volume at maximum desire to void (Vmdv). In cases treated by radical hysterectomy alone, Cmdv decreased immediatelly after the operation and then maximum urethral closure pressure (cPura) gradually decreased. Concerning the cases treated by radical hysterectomy and radiation, severe low Cmdv and severe low Vmdv appeared 5 years after the treatment for uterine cancer in almost all cases, and low cPura appeared immediately after the operation in half of the cases. Treatment with beta 2-stimulant significantly improved urinary frequency, voided volume and urinary incontinence. In UDS findings, Vmdv and Cmdv were significantly improved by the treatment with beta 2-stimulant. The functional profile length and cPura value were not significantly changed. In uroflowmetry, the maximum flow rate and average flow rate were significantly improved by the treatment with beta 2-stimulant.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Agonists↗
PubMed1992

Gene analyses of abnormal fibrinogens with a mutation in the gamma chain.

In four abnormal fibrinogens with a point mutation in the gamma chain, all characterized by impaired fibrin polymerization, we identified single base exchanges in the respective mutant gamma chain genes by polymerase chain reaction followed by DNA sequence analysis. These base exchanges accounted for the amino acid substitutions previously reported from our laboratory. They were exchanges of C to T (CGC for gamma Arg-275 to TGC for Cys) in fibrinogen Osaka II, T to G (AAT for gamma Asn-308 to AAG for Lys) in fibrinogen Kyoto I, T to C (ATG for gamma Met-310 to ACG for Thr) in fibrinogen Asahi, and G to T (GAT for gamma Asp-330 to TAT for Tyr) in fibrinogen Kyoto III. These base exchanges were found to reside in exon VIII of the gamma chain gene. Since many abnormal molecules are associated with polymerization defects, unless associated with the impaired release of fibrinopeptides A and/or B, exon VIII of the gamma chain gene may deserve careful study to define the structural alterations.

DNA Mutational Analysis↗
PubMed1992

[Flow cytometric analysis of proliferative characteristics of human leukemic cells in bone marrows in vivo using bromodeoxyuridine (BrdU) and its monoclonal antibody].

We developed a new method for analyzing the proliferative characteristics of human acute leukemic cells in bone marrows in vivo using BrdU and its monoclonal antibody. The thirty minutes after a bolus BrdU infusion, a 1st bone marrow aspiration (BMP) was performed to calculate BrdU-LI. Then, a 150-minute continuous infusion of BrdU was started. After the infusion, a 2nd BMP was done to calculate the increasing rate of the BrdU-LI for 3 hours. Each of the bone marrow cells was analyzed by FCM. A mean value of 10.4% for BrdU-LI in 22 previously untreated patients was obtained. In 3 of the patients, Ts and Tpot ranged from 13.5 to 33.9 hours and 6.8 to 10.7 days respectively.

Acute Disease↗
PubMed1992

Herniation of an antral polyp through an oroantral fistula.

This paper reports a case of herniation of an antral polyp through an oroantral fistula, appearing as a polypoid lesion of the alveolar ridge. The patient was a 24-year-old female, and her upper molar had been extracted two months previously. The lesion was asymptomatic, and was a soft tissue mass, red in color and nontender to palpation, involving the alveolar ridge in the maxillary molar area. Review of the literature yielded only a few other such cases.

Adult↗
PubMed1992

[Sensitivity test for anti-tumor agents-3. MTT assay and its clinical effect].

MTT assay, a sensitivity test of anti-tumor agents was performed, and its clinical usefulness, was discussed. In 15 surgical specimens, the cell suspensions were prepared aseptically, and divided into three processing; namely, Papanicolaou (Pap) smears to confirm the malignant cells, MTT assay, and cell cultures in chamber slides. MTT assay was evaluated only when tumor cells in the chamber slide were observed 50% or more by Pap staining. Drugs judged to be effective were applied for patients, resulting in 64.2% of predictive accuracy in the sensitivity. Conclusions; 1) MTT assay was developed for sensitivity test of anti-tumor agents, 2) Strict assessment was carried out by the confirmation of cancer cells using chamber slides, 3) On clinical usefulness, predictability for the sensitivity was 64.2%, that for resistance was 100%, and over all predictability was 66.7% 4) MTT assay was useful for the determination of effective and for elimination of ineffective drugs.

Antineoplastic Agents↗
PubMed1992

[Development of method for measurement of pulsatile change in arterial diameter in the fetus].

The present study was designed to evaluate perfusion dynamics of organs by measuring pulsatile change in arterial diameter concomitant with flow velocity determination. An ultrasonic phased locked echo tracking system equipped with a real time linear array scanner was used to measure pulsatile change in arterial diameter. The distance from the transducer to a distal or proximal point on the inner vessel wall can be defined as the relative time difference of the zero cross for each reflective wave. The pulsatile change in the arterial diameter was a reflection of intra-arterial pressure change which was confirmed by simultaneous measurement of direct pressure in the adult brachial, femoral and descending aorta (DA) by arterial catheterization. The accuracy of measurement of arterial diameter and pulsatile change were confirmed by the coefficient of variation (C.V) in the diameter of than 4% in the former and less than 8% in the later in both inter- and intra-assay variance. In normal growth fetuses, the pulsatile changes in the DA were within the range of about 10% of the minimum arterial diameter. Intrauterine growth retarded fetuses (IUGR) who had a high pulsatility index (PI) were 7.26 +/- 0.36% (n = 5, p < 0.01 v.s. normal growth group) and showed discrete figures between pulsatile and blood flow velocity waveforms. Furthermore, large for date fetuses (LFD) who had a high PI were 12.20 +/- 0.50% (n = 3, p < 0.05 v.s. normal growth group) and had similar figures in pulsatile and blood flow velocity waveforms.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1992

Serovar, biotype, phage type, toxigenicity & antibiotic susceptibility patterns of Vibrio cholerae isolated during two consecutive cholera seasons (1989-90) in Calcutta.

Characteristics of V. cholerae isolated from patients of acute secretory diarrhoea admitted to the Infectious Diseases Hospital, Calcutta during two consecutive cholera seasons (1989 and 1990), with special emphasis on biotyping and toxigenicity, were investigated. The isolation rates of V. cholerae during 1989 and 1990 were 78 and 85.1 per cent respectively, with Inaba serotype dominating in 1989 and Ogawa in 1990. All the V. cholerae 01 strains isolated in this study belonged to biotype Eltor with phage type 4 dominating (48.8%). Most of the strains of V. cholerae were resistant to 10 and 150 micrograms/ml of 0/129 vibriostatic agent. Similarly, majority of the V. cholerae strains were resistant to furazolidone (95.7%), cotrimoxazole (83%) and tetracycline (63.1%) and several resistance patterns were encountered. All the V. cholerae 01 strains examined produced cholera toxin (CT) in amounts ranging between greater than 70 pg/ml and greater than 2.5 ng/ml. In contrast, all but one of the non-01 strains isolated in this study did not produce CT. Further studies are required to elucidate the mechanism involved in the pathogenesis of non-01 V. cholerae mediated diarrhoea.

Anti-Bacterial Agents↗